KPV

A Second Claim, With a Different Mechanism

UKPWritten and published by UK Peptides3 min readUpdated 3 cited sources

The short answer

Two papers from 2000 reported antimicrobial activity for alpha-MSH peptides including the KPV fragment, against Staphylococcus aureus and Candida albicans. The proposed mechanism was an increase in microbial cyclic AMP, which is unrelated to the transporter route that explains the anti-inflammatory work.

Key facts

Primary paper
Cutuli M et al., J Leukoc Biol 2000 (PMID 10670585)
Companion review
Catania A et al., Ann N Y Acad Sci 2000 (PMID 11268348)
Organisms tested
Staphylococcus aureus, Candida albicans
Concentration range reported
Broad, including picomolar
Proposed mechanism
Increased cellular cAMP in the microorganism
Mechanistic test used
Dideoxyadenosine, an adenylyl cyclase inhibitor
Effect on neutrophil killing
Enhanced, not reduced
Human evidence
None

What was reported

Cutuli and colleagues tested alpha-MSH peptides against two organisms chosen as representative pathogens: the gram-positive bacterium Staphylococcus aureus and the yeast Candida albicans. The peptides significantly inhibited S. aureus colony formation and reversed the enhancing effect of urokinase on colony formation. Small concentrations reduced both the viability and the germ tube formation of C. albicans. Effects were reported across a broad concentration range including the picomolar. The companion review by Catania and colleagues states the fragment result explicitly: alpha-MSH and its fragment KPV showed inhibitory influences against S. aureus and C. albicans.

The proposed mechanism, and how it was probed

The suggested route was that these peptides raise cyclic AMP inside the microorganism. Two observations support it. Cyclic AMP was significantly increased in peptide-treated yeast, and dideoxyadenosine (a potent inhibitor of adenylyl cyclase, the enzyme that makes cyclic AMP) partly reversed the killing activity. Partly is the operative word: a partial reversal implicates the pathway without establishing that it accounts for the whole effect, and leaves room for something else contributing.

Research material referenced

KPV 10mg, third-party HPLC tested

Buy KPV · £28.99

Why this is a separate claim

This is the point most summaries lose. The anti-inflammatory account of KPV runs through PepT1 carrying the tripeptide into a mammalian cell, where it dampens NF-kappaB and MAP kinase signalling. The antimicrobial account runs through raising cyclic AMP inside a bacterium or a yeast. Different organism, different target, different second messenger, different direction. One story is about suppressing a signalling cascade in a host cell, the other about disturbing signalling in a microbe. They are not two faces of one property, and a description that welds them together into a single 'anti-inflammatory and antimicrobial' characteristic is describing something that has not been shown to exist.

The counterintuitive result about neutrophils

There is a standing problem with anti-inflammatory agents: suppressing inflammation tends to reduce the killing of pathogens, which is why immunosuppression and infection travel together. Cutuli and colleagues tested this directly, asking whether alpha-MSH reduced killing of C. albicans and S. aureus by human neutrophils. It did not. Killing was enhanced rather than reduced, which the authors attribute to the direct antimicrobial activity of the peptides. That is an interesting result because the expected direction is the opposite one, and it is the part of this work that would matter most if it held up.

How much weight this literature can carry

Not much on its own, and the reasons are structural rather than a criticism of the work. Both papers are from 2000. Both are in vitro. The specific fragment result for KPV is stated most clearly in a conference-proceedings review rather than in a primary experimental report, which is a weaker place for a load-bearing claim to sit. Two organisms is not a spectrum. And there has been no substantial follow-up establishing an antimicrobial application in the twenty-six years since, which for a promising antimicrobial finding is itself informative.

What is not being claimed

That KPV is an antibiotic, an antifungal, or a treatment for infection of any kind. It is not, it has never been tested as one in a person, and no regulator anywhere has assessed it for anything. This article describes what two papers reported in laboratory organisms. KPV is supplied here as a material for laboratory research only.

Frequently asked questions

Does KPV kill bacteria?

Two in vitro papers from 2000 reported inhibitory effects against one bacterium and one yeast. That is a laboratory observation in two organisms, not a demonstration of antimicrobial activity in any useful sense, and it has not been developed further in the intervening years.

Why would a peptide raise cAMP in a yeast?

Cyclic AMP signalling is ancient and present across kingdoms, including in fungi where it regulates morphological switching such as germ tube formation. A compound that perturbs adenylyl cyclase activity in a yeast is disturbing a real regulatory system. That is a plausible mechanism, though the partial reversal by an adenylyl cyclase inhibitor shows it is not the whole story.

Does the antimicrobial claim depend on PepT1?

No, and that is one reason to treat the two claims separately. PepT1 is a mammalian intestinal transporter. Whatever route these peptides take into a bacterium or a yeast, it is not that one.

Is picomolar activity plausible?

It is what the paper reports and it is unusual: picomolar potency normally implies a high-affinity specific target. It is one of the reasons the finding would be worth replicating with modern methods, and one of the reasons a single 2000 paper is thin ground on which to build a claim.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More KPV articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.